Investment industry veteran Mr. Brian Cherry appointed to Board of Directors Dr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive...
Positive Phase 3 HERIZON-GEA-01 results for Ziihera ® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma ( GEA) presented at ASCO GI Up to $440.0 million in...
Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the...
• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera ® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present...
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline...
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END
MarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased...
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse...
Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholders Strategic initiative follows positive topline results from pivotal...
The S&P 500 Index ($SPX ) (SPY ) on Monday fell by -0.92%, the Dow Jones Industrials Index ($DOWI ) (DIA ) fell by -1.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) fell by -0.83%. December E-mini S&P...